drugset / Trial / NCT02032134

Protocol for the Infusion of Buffy Coat-derived Cryopreserved Platelets in Patients With Severe Thrombocytopenia

NCT02032134 ↗

Phase 4 Terminated 5 enrolled Napolitano Mariasanta Regione Sicilia · collab
NaSingle-groupOpen-labelTreatment

Summary

The increasing need for blood components and the increasingly careful donor selection procedures, make the availability of blood components very reduced, in particular for platelets that are currently administered preferably "fresh" or cryopreserved, only in emergency conditions. Exceeding this limit through the spread of use of cryopreserved platelets in the common clinical practice, might help clinicians to avoid wasting valuable products and face periods of particular shortage of donors Some studies already published in the literature over the last decade (1,2) have demonstrated the safety and efficacy of autologous cryopreserved platelets . The main objective of the proposed study is to evaluate the efficacy and safety of platelets, cryopreserved with DMSO using a a new method, in patients with severe thrombocytopenia. This is the in vivo phase of a study where availability and efficacy of cryopreserved platelets has been assessed in vitro.

Timeline

Start
2015-07
Primary completion
2016-06
Completion
2016-06

Outcome

Outcome not reported

Stopped (Enrollment): “recruitment failure within the interval of available CRY BC-PLTs for the study”

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject CRY BC-PLTs Unknown 1 unknown Other